Pok-Ja Oh1, Jung Ran Lee2, Sook-Kyoung Kim3, Jeong-Hye Kim4. 1. Department of Nursing, Sahmyook University, Seoul, South Korea. Electronic address: ohpjKorea@gmail.com. 2. Korea Cancer Center Hospital, Seoul, South Korea. 3. National Cancer Center, Seoul, South Korea. 4. Department of Clinical Nursing, Ulsan University, Seoul, South Korea.
Abstract
PURPOSE: This study was conducted to identify the changes in oxaliplatin-induced peripheral neuropathy (OIPN), disturbance in activities of daily living (ADL), and depression and their interrelationships during the cancer care trajectory in colorectal cancer patients. METHODS: Eighty-six subjects participated in the study and completed the questionnaire at three time points: pre-chemotherapy, undergoing chemotherapy, and 3 months after the completion of chemotherapy. The assessment tools were Chemotherapy-Induced Peripheral Neuropathy 20 for OIPN, Chemotherapy-Induced Peripheral Neuropathy Assessment Tool to measure disturbances in ADL, and Hospital Anxiety and Depression Scale for depression. Data were analyzed using descriptive statistics and repeated-measures analysis of variance. RESULTS: While undergoing chemotherapy, 37.2% of the patients complained of OIPN and 32.6% exhibited OIPN at 3-month follow-up. Repeated-measures analysis of variance showed a significant increase in OIPN after chemotherapy, which remained high at the 3-month follow-up. The most frequent symptom of OIPN was "tingling feeling in the hand and foot," and the second was "impotence." Disturbance in ADL by OIPN and depression showed similar patterns as OIPN. The mean score for disturbance in ADL of OIPN was 48.58. The mean score was 7.36 for depression, with a prevalence of 23.5%. There were significant correlations among the three variables, suggesting that OIPN may be casual in the OIPN- disturbance in ADL-depression symptom interrelationships. CONCLUSION: These results suggest that chemotherapy is highly associated with OIPN, disturbance in ADL by OIPN, and depression in colorectal cancer patients. Nursing intervention is needed to relieve depression as well as OIPN in patients undergoing chemotherapy.
PURPOSE: This study was conducted to identify the changes in oxaliplatin-induced peripheral neuropathy (OIPN), disturbance in activities of daily living (ADL), and depression and their interrelationships during the cancer care trajectory in colorectal cancerpatients. METHODS: Eighty-six subjects participated in the study and completed the questionnaire at three time points: pre-chemotherapy, undergoing chemotherapy, and 3 months after the completion of chemotherapy. The assessment tools were Chemotherapy-Induced Peripheral Neuropathy 20 for OIPN, Chemotherapy-Induced Peripheral Neuropathy Assessment Tool to measure disturbances in ADL, and Hospital Anxiety and Depression Scale for depression. Data were analyzed using descriptive statistics and repeated-measures analysis of variance. RESULTS: While undergoing chemotherapy, 37.2% of the patients complained of OIPN and 32.6% exhibited OIPN at 3-month follow-up. Repeated-measures analysis of variance showed a significant increase in OIPN after chemotherapy, which remained high at the 3-month follow-up. The most frequent symptom of OIPN was "tingling feeling in the hand and foot," and the second was "impotence." Disturbance in ADL by OIPN and depression showed similar patterns as OIPN. The mean score for disturbance in ADL of OIPN was 48.58. The mean score was 7.36 for depression, with a prevalence of 23.5%. There were significant correlations among the three variables, suggesting that OIPN may be casual in the OIPN- disturbance in ADL-depression symptom interrelationships. CONCLUSION: These results suggest that chemotherapy is highly associated with OIPN, disturbance in ADL by OIPN, and depression in colorectal cancerpatients. Nursing intervention is needed to relieve depression as well as OIPN in patients undergoing chemotherapy.
Authors: Julie A Meade; Alison N Fowlkes; Mackinsey J Wood; Mary Claire Kurtz; Madeline M May; Wisam B Toma; Urszula O Warncke; Jared Mann; Mohammed Mustafa; Aron H Lichtman; M Imad Damaj Journal: Behav Pharmacol Date: 2021-08-01 Impact factor: 2.277
Authors: Cynthia S Bonhof; Lonneke V van de Poll-Franse; Dareczka K Wasowicz; Laurens V Beerepoot; Gerard Vreugdenhil; Floortje Mols Journal: J Cancer Surviv Date: 2020-11-13 Impact factor: 4.442
Authors: Hsing-Wei Hung; Chien-Ying Liu; Hsiu-Fang Chen; Chun-Chu Chang; Shu-Ching Chen Journal: Int J Environ Res Public Health Date: 2021-05-26 Impact factor: 3.390